InvestorsHub Logo
Followers 10
Posts 782
Boards Moderated 0
Alias Born 02/08/2007

Re: DewDiligence post# 543

Thursday, 01/31/2019 10:18:57 PM

Thursday, January 31, 2019 10:18:57 PM

Post# of 7698
<<Setting the optimal price is a guessing game, but a significantly steeper discount than Dysport and Xeomin could well be counterproductive for EOLS and its physician partners. >>

Win some lose some:


The rival treatment by Daewoong and Evolus -- to be priced 25 percent lower -- could be its biggest threat. Madison, New Jersey-based Allergan and Medytox are testing a next-generation drug using the new secret manufacturing process but it’s not expected to get U.S. regulatory approval until 2022.

“Daewoong and Evolus are able to introduce DWP-450 into the U.S. market at a price that they have touted will be substantially lower than the price of Botox, and to thereby undercut the market for Botox
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent RVNC News